1
|
Cenalmor A, Pascual E, Gil-Manso S, Correa-Rocha R, Suárez JR, García-Álvarez I. Evaluation of Anti-Neuroinflammatory Activity of Isatin Derivatives in Activated Microglia. Molecules 2023; 28:4882. [PMID: 37375437 DOI: 10.3390/molecules28124882] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2023] [Revised: 06/14/2023] [Accepted: 06/19/2023] [Indexed: 06/29/2023] Open
Abstract
Neuroinflammation plays a crucial role in the progression of Alzheimer's disease and other neurodegenerative disorders. Overactivated microglia cause neurotoxicity and prolong the inflammatory response in many neuropathologies. In this study, we have synthesised a series of isatin derivatives to evaluate their anti-neuroinflammatory potential using lipopolysaccharide activated microglia as a cell model. We explored four different substitutions of the isatin moiety by testing their anti-neuroinflammatory activity on BV2 microglia cells. Based on the low cytotoxicity and the activity in reducing the release of nitric oxide, pro-inflammatory interleukin 6 and tumour necrosis factor α by microglial cells, the N1-alkylated compound 10 and the chlorinated 20 showed the best results at 25 µM. Taken together, the data suggest that 10 and 20 are promising lead compounds for developing new neuroprotective agents.
Collapse
Affiliation(s)
- Alejandro Cenalmor
- Facultad de Ciencias Experimentales, Universidad Francisco de Vitoria, Pozuelo de Alarcón, 28223 Madrid, Spain
| | - Elena Pascual
- Facultad de Ciencias Experimentales, Universidad Francisco de Vitoria, Pozuelo de Alarcón, 28223 Madrid, Spain
| | - Sergio Gil-Manso
- Laboratory of Immune-Regulation, Gregorio Marañón Health Research Institute (IISGM), 28009 Madrid, Spain
| | - Rafael Correa-Rocha
- Laboratory of Immune-Regulation, Gregorio Marañón Health Research Institute (IISGM), 28009 Madrid, Spain
| | - José Ramón Suárez
- Departamento de Química en Ciencias Farmacéuticas, Facultad de Farmacia, Universidad Complutense de Madrid, 28040 Madrid, Spain
| | - Isabel García-Álvarez
- Facultad de Ciencias Experimentales, Universidad Francisco de Vitoria, Pozuelo de Alarcón, 28223 Madrid, Spain
| |
Collapse
|
2
|
Cheke RS, Patil VM, Firke SD, Ambhore JP, Ansari IA, Patel HM, Shinde SD, Pasupuleti VR, Hassan MI, Adnan M, Kadri A, Snoussi M. Therapeutic Outcomes of Isatin and Its Derivatives against Multiple Diseases: Recent Developments in Drug Discovery. Pharmaceuticals (Basel) 2022; 15:ph15030272. [PMID: 35337070 PMCID: PMC8950263 DOI: 10.3390/ph15030272] [Citation(s) in RCA: 30] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2021] [Revised: 01/29/2022] [Accepted: 01/30/2022] [Indexed: 12/22/2022] Open
Abstract
Isatin (1H indole 2, 3-dione) is a heterocyclic, endogenous lead molecule recognized in humans and different plants. The isatin nucleus and its derivatives are owed the attention of researchers due to their diverse pharmacological activities such as anticancer, anti-TB, antifungal, antimicrobial, antioxidant, anti-inflammatory, anticonvulsant, anti-HIV, and so on. Many research chemists take advantage of the gentle structure of isatins, such as NH at position 1 and carbonyl functions at positions 2 and 3, for designing biologically active analogues via different approaches. Literature surveys based on reported preclinical, clinical, and patented details confirm the multitarget profile of isatin analogues and thus their importance in the field of medicinal chemistry as a potent chemotherapeutic agent. This review represents the recent development of isatin analogues possessing potential pharmacological action in the years 2016–2020. The structure–activity relationship is also discussed to provide a pharmacophoric pattern that may contribute in the future to the design and synthesis of potent and less toxic therapeutics.
Collapse
Affiliation(s)
- Rameshwar S. Cheke
- Department of Pharmaceutical Chemistry, Dr. Rajendra Gode College of Pharmacy, Malkapur 443101, Maharashtra, India;
- Correspondence: (R.S.C.); (V.R.P.)
| | - Vaishali M. Patil
- Department of Pharmaceutical Chemistry, KIET School of Pharmacy, KIET Group of Institutions, Delhi-NCR, Ghaziabad 201206, Uttar Pradesh, India;
| | - Sandip D. Firke
- Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur 425405, Maharashtra, India; (S.D.F.); (I.A.A.); (H.M.P.)
| | - Jaya P. Ambhore
- Department of Pharmaceutical Chemistry, Dr. Rajendra Gode College of Pharmacy, Malkapur 443101, Maharashtra, India;
| | - Iqrar A. Ansari
- Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur 425405, Maharashtra, India; (S.D.F.); (I.A.A.); (H.M.P.)
| | - Harun M. Patel
- Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur 425405, Maharashtra, India; (S.D.F.); (I.A.A.); (H.M.P.)
| | - Sachin D. Shinde
- Department of Pharmacology, Shri. R. D. Bhakt College of Pharmacy, Jalna 431213, Maharashtra, India;
| | - Visweswara Rao Pasupuleti
- Department of Biomedical Sciences and Therapeutics, Faculty of Medicine & Health Sciences, University Malaysia Sabah, Kota Kinabalu 44800, Sabah, Malaysia
- Department of Biochemistry, Faculty of Medicine and Health Sciences, Abdurrab University, Pekanbaru 28291, Riau, Indonesia
- Centre for International Collaboration and Research, Reva University, Rukmini Knowledge Park, Kattigenahalli, Yelahanka, Bangalore 560064, Karnataka, India
- Correspondence: (R.S.C.); (V.R.P.)
| | - Md Imtaiyaz Hassan
- Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi 110025, India;
| | - Mohd Adnan
- Department of Biology, College of Science, University of Hail, Hail P.O. Box 2440, Ha′il 2440, Saudi Arabia; (M.A.); (M.S.)
| | - Adel Kadri
- Faculty of Science of Sfax, Department of Chemistry, University of Sfax, B.P. 1171, Sfax 3000, Tunisia;
- Faculty of Science and Arts in Baljurashi, Albaha University, P.O. Box 1988, Albaha 65527, Saudi Arabia
| | - Mejdi Snoussi
- Department of Biology, College of Science, University of Hail, Hail P.O. Box 2440, Ha′il 2440, Saudi Arabia; (M.A.); (M.S.)
- Laboratory of Genetics, Biodiversity and Valorization of Bio-Resources (LR11ES41), University of Monastir, Higher Institute of Biotechnology of Monastir, Avenue Tahar Haddad, BP74, Monastir 5000, Tunisia
| |
Collapse
|
3
|
Moghaddam‐manesh M, Beyzaei H, Heidari Majd M, Hosseinzadegan S, Ghazvini K. Investigation and comparison of biological effects of regioselectively synthesized thiazole derivatives. J Heterocycl Chem 2021. [DOI: 10.1002/jhet.4278] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Affiliation(s)
- Mohammadreza Moghaddam‐manesh
- General Bureau of Standard Sistan and Baluchestan Province Iranian National Standards Organization Zahedan Iran
- Noncommunicable Diseases Research Center Bam University of Medical Sciences Bam Iran
| | - Hamid Beyzaei
- Department of Chemistry, Faculty of Science University of Zabol Zabol Iran
| | - Mostafa Heidari Majd
- Department of Medicinal Chemistry, Faculty of Pharmacy Zabol University of Medical Sciences Zabol Iran
| | - Sara Hosseinzadegan
- Department of Chemistry, Faculty of Science University of Sistan and Baluchestan Zahedan Iran
| | - Kiarash Ghazvini
- Department of of Mycobacteriology, Ghaem Hospital Mashhad University of Medical Sciences Mashhad Iran
| |
Collapse
|
4
|
Ding Z, Zhou M, Zeng C. Recent advances in isatin hybrids as potential anticancer agents. Arch Pharm (Weinheim) 2020; 353:e1900367. [PMID: 31960987 DOI: 10.1002/ardp.201900367] [Citation(s) in RCA: 65] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2019] [Revised: 12/27/2019] [Accepted: 12/28/2019] [Indexed: 11/06/2022]
Abstract
The isatin framework is a useful template for the development of novel anticancer agents. This is exemplified by the fact that several isatin-based anticancer agents, such as semaxanib, sunitinib, nintedanib, and hesperadin, are already in use or under clinical trials for the treatment of diverse kinds of cancers. Isatin-based hybrids could be obtained by incorporating other anticancer pharmacophores into the isatin skeleton and they have the potential to overcome drug resistance with reduced side effects. Thus, isatin-based hybrids may provide attractive scaffolds for the development of novel anticancer agents. This review covers the recent advances of isatin-based hybrids with anticancer activity, covering articles published between 2001 and 2019. The anticancer activities of these molecules and the structure-activity relationships are also discussed. The purpose of this review article is to set up the direction for the design and development of isatin-based hybrids with high efficacy and low toxicity.
Collapse
Affiliation(s)
- Zhen Ding
- Department of Pharmacy, Bozhou People's Hospital, Bozhou, China
| | - Minfeng Zhou
- Department of General Practice, Zhuji Affiliated Hospital of Shaoxing University, Shaoxing, China
| | - Cheng Zeng
- Department of Pharmacy, Bozhou People's Hospital, Bozhou, China
| |
Collapse
|